Eflucimibe

• CAT Number: I006627
• CAS Number: 202340-45-2
• Molecular Formula: C29H43NO2S
• Molecular Weight: 469.72
• Purity: ≥95%
• Synonyms: Eflucimibe; F-12511; L-0081; F12511; L0081.;(S)-2-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide
• Target: ACAT inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: (2S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide
• InChI: InChI=1S/C29H43NO2S/c1-5-6-7-8-9-10-11-12-13-17-20-33-28(25-18-15-14-16-19-25)29(32)30-26-21-22(2)27(31)24(4)23(26)3/h14-16,18-19,21,28,31H,5-13,17,20H2,1-4H3,(H,30,32)/t28-/m0/s1
• InChIKey: ZXEIEKDGPVTZLD-NDEPHWFRSA-N
• SMILES: CCCCCCCCCCCCS[C@@H](C1=CC=CC=C1)C(=O)NC2=C(C(=C(C(=C2)C)O)C)C

Eflucimibe（Cat No.:I006627）is an experimental drug being developed for the treatment of hypercholesterolemia (high cholesterol) and atherosclerosis (hardening of the arteries). It works by inhibiting the enzyme acyl-CoA:cholesterol acyltransferase (ACAT), which plays a role in cholesterol esterification. By blocking this enzyme, eflucimibe reduces the accumulation of cholesterol in arterial walls, potentially preventing plaque buildup and lowering cholesterol levels. Although promising in preclinical studies and early trials, its safety and long-term effectiveness are still under investigation. Eflucimibe may offer an alternative treatment for cardiovascular diseases if further research proves successful.